Welcome to our dedicated page for DBV Technologies S.A. news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies S.A. stock.
DBV Technologies S.A. (symbol: DBVT) is a clinical-stage specialty biopharmaceutical company revolutionizing the treatment of food allergies, a significant and growing public health issue. Founded in 2002, the company has developed a groundbreaking technology platform known as Viaskin®.
Viaskin® employs epicutaneous immunotherapy (EPIT), a proprietary method that administers allergens through an epicutaneous patch applied to intact skin. This innovative approach targets Langerhans cells, specialized immune cells in the skin, which capture the allergen and migrate to the lymph nodes. This mechanism allows for activation of the immune system without introducing the allergen into the bloodstream, thus minimizing systemic exposure and the risk of severe allergic reactions.
DBV Technologies' flagship product, Viaskin Peanut, is designed for peanut-allergic patients. The patch aims to improve patient tolerability to peanuts and significantly reduce the risk of life-threatening allergic reactions upon accidental exposure. Clinical trials have demonstrated the product's efficacy and safety, making it a promising solution for millions of individuals affected by peanut allergies.
In addition to peanut allergies, DBV Technologies is expanding its portfolio to address other food allergies like milk. The company's robust pipeline and innovative approach position it at the forefront of allergy treatment research.
DBV Technologies has secured multiple worldwide patents for its Viaskin® technology, underlining its pioneering role in the field of immunotherapy. The company continually collaborates with leading research institutions and partners to advance its clinical programs and bring new therapies to market.
Recent achievements include significant milestones in clinical trials, regulatory submissions, and strategic partnerships, reflecting DBV Technologies' commitment to developing safe and effective treatments for food allergies. The company's dedication to addressing unmet medical needs ensures it remains a crucial player in the biopharmaceutical landscape.
DBV Technologies held its Ordinary and Extraordinary General Meeting on May 12, 2022, where shareholders approved all proposed resolutions from the Board of Directors. The meeting, chaired by Michel de Rosen, confirmed the company's ongoing commitment to its strategic initiatives.
DBV Technologies is advancing Viaskin™, a proprietary platform for non-invasive immunotherapy aimed at treating food allergies, including clinical trials for Viaskin Peanut. For more information, visit the investors section of their website.
DBV Technologies has successfully completed the sale of American Depositary Shares (ADSs) raising $15.3 million through its At-The-Market program. The sale involved issuing 12,072,476 new ADSs, equivalent to 6,036,238 ordinary shares, resulting in a dilution of approximately 9.9% to existing shareholders. This capital increase will facilitate the company’s ongoing clinical trials for its Viaskin immunotherapy platform, aiming to enhance treatment options for food allergies. The delivery of new shares is scheduled for May 6, 2022.
DBV Technologies has announced an At-The-Market (ATM) program on Nasdaq, allowing it to raise up to $100 million through the sale of American Depositary Shares (ADS). This program, effective until July 16, 2024, will support the potential approval and launch of Viaskin™ Peanut and advance the development of other products. The plan involves selling up to 16,528,961 ordinary shares, potentially leading to a dilution of around 30%. Jefferies LLC will act as the sales agent, and the proceeds will also cover general corporate purposes.
DBV Technologies reported updates on the regulatory status of its lead product, Viaskin Peanut, following a Type C meeting granted by the FDA. This meeting is aimed at aligning on the new Phase 3 study protocol submitted as part of the FDA's briefing materials. Additionally, the company announced its first-quarter 2022 financial results, which were approved by the Board of Directors on April 29, 2022.
DBV Technologies announced a conference call for May 2, 2022, at 5:00 p.m. ET to discuss its first quarter 2022 financial results and corporate updates. The call will be available via teleconference and live webcast. DBV is focused on developing Viaskin™, a platform for epicutaneous immunotherapy aimed at treating food allergies, with ongoing trials for Viaskin Peanut. The company's shares are traded on Euronext and Nasdaq under the symbols DBV and DBVT, respectively.
DBV Technologies will hold its Ordinary and Extraordinary General Meeting on May 12, 2022, at 8:30 a.m. CEST in Montrouge, France. Preparatory documents are available on the company's website and via the French Bulletin des Annonces Légales Obligatoires. Shareholders can request documents until May 7, 2022, and the meeting will also be webcast live. DBV is focused on developing Viaskin™, an innovative platform for immunotherapy targeted at food allergies, with ongoing clinical trials for Viaskin Peanut.
The monthly report as of March 31, 2022, reveals that DBVT has a total of 55,095,537 shares outstanding. The total number of voting rights attached to these shares is 55,095,537, with a net total of 54,951,036 voting rights. This net total accounts for shares without voting rights. The report is compliant with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and is intended for shareholders and market observers.
DBV Technologies will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 17, 2022, at 10:00 a.m. ET. Dr. Pharis Mohideen, the Chief Medical Officer, is set to deliver the presentation. Investors can access the webcast on the company's website, with a replay available for about 90 days post-event. DBV Technologies focuses on developing Viaskin™, an innovative technology platform for immunotherapy, particularly aimed at food allergies, with ongoing trials for Viaskin Peanut.
DBVT announced its monthly update as of February 28, 2022, regarding the total number of shares and voting rights. The company reported a total of 55,095,762 shares, with a total gross of 55,095,762 voting rights. After accounting for shares without voting rights, the total net voting rights stood at 54,919,952. This information is in compliance with the General Regulations of the Autorité des Marchés Financiers.
FAQ
What is the current stock price of DBV Technologies S.A. (DBVT)?
What is the market cap of DBV Technologies S.A. (DBVT)?
What does DBV Technologies S.A. specialize in?
What is Viaskin® technology?
What is Viaskin Peanut?
How does Viaskin® technology minimize the risk of allergic reactions?
What other food allergies is DBV Technologies targeting?
When was DBV Technologies founded?
What are some recent achievements of DBV Technologies?
What is the significance of DBV Technologies' patents?
How does DBV Technologies collaborate with other institutions?
What is the financial condition of DBV Technologies?
